AACR roundup: Checkpoint cocktails score early successes as Roche's triple shows high response rate in frontline triple negative breast cancer
Roche today spelled out its best early-stage case for a new triple therapy combo to tackle triple negative breast cancer — a particularly lethal variety of cancer that has proven tough to treat.
Read on for more: Little TG Therapeutics looks for applause on latest umbralisib data; Add-on from Chi-Med, AstraZeneca helps Tagrisso-resistant lung cancer patients; Astellas spells out positive Xospata PhIII data in AML patients; Preclinical neoantigen study finds 4 promising targets for spurring an immune response
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.